AngioLab, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1999-06-03
- Employees
- 16
- Market Cap
- -
- Website
- http://www.angiolab.co.kr
Clinical Trials
3
Active:0
Completed:3
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)A Study to Evaluate the Efficacy and Safety of ALH-L1005 in Patients With Chronic Periodontitis
Phase 2
Completed
- Conditions
- Chronic Periodontitis
- Interventions
- Drug: PlaceboDrug: ALH-L1005 600mg/dayDrug: ALH-L1005 1,200mg/day
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- AngioLab, Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT04503746
- Locations
- 🇰🇷
AngioLab, Inc., Daejeon, Daejeon Gwangyeogsi, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH
Phase 2
Completed
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo oral tabletDrug: ALS-L1023 1,200mgDrug: ALS-L1023 1,800mg
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- AngioLab, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04342793
- Locations
- 🇰🇷
Hanyang University Seoul Hospital, Seoul, Korea, Republic of
Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD
Phase 2
Completed
- Conditions
- Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- AngioLab, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT03725501
- Locations
- 🇰🇷
AngioLab, Inc., Daejeon, Daejeon Gwangyeogsi, Korea, Republic of
News
No news found